Evidence map›Paper›PMID 32458153›Full record

ReviewCurrent rheumatology reports2020

Reactive Arthritis: Treatment Challenges and Future Perspectives.

Daniel Wendling, Clément Prati, Mickael Chouk, Frank Verhoeven

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. [Reactive arthritis].Zeitschrift fur Rheumatologie · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Revue du rhumatisme (Ed. francaise : 1993) · 2021
    Article
  13. Rheumatological complications of Covid 19.Autoimmunity reviews · 2021
    Review
  14. Reactive arthritis after COVID-19.BMJ case reports · 2021
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Daniel WendlingDepartment of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France. dwendling@chu-besancon.fr.
Clément PratiDepartment of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France.
Mickael ChoukDepartment of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France.
Frank VerhoevenDepartment of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France.
Centre Hospitalier Universitaire de Besançon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewReactive arthritis is synovitis related to an infection away from the joint. The evolution is variable, frequently self-limited, but with the possible evolution to a prolonged form, generating functional incapacity and sequelae. RECENT

findingsNew microbiological families have been incriminated and pathophysiological links have been clarified, highlighting the role of the mucous membranes (gut in particular), specific cell populations, and the production of pro-inflammatory cytokines. First-line pharmacological treatment is based on NSAIDs. In case of failure, synthetic and more recently biological DMARDs are indicated. Only open data are available for biological DMARDs but suggest good efficacy and safety. Reactive arthritis has not disappeared. The diagnosis must be mentioned by the clinic and history to allow the rapid introduction of an appropriate treatment.

Indexed as

Antirheumatic AgentsArthritis, ReactiveSynovitisAnti-Inflammatory Agents, Non-SteroidalCytokinesHumansAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsCytokinesAnti-TNF agentsBiodrugsInterleukin-17Interleukin-23Reactive arthritisSpondyloarthritisTreatment

Identifiers

PMID32458153
OpenAlexW3028695564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.